These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25813347)

  • 1. Smoothened mutations underlie Basal cell carcinoma resistance.
    Cancer Discov; 2015 May; 5(5):OF9. PubMed ID: 25813347
    [No Abstract]   [Full Text] [Related]  

  • 2. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
    Ridky TW; Cotsarelis G
    Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
    J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
    [No Abstract]   [Full Text] [Related]  

  • 4. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
    Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
    Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
    Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
    Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
    Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
    Mohan SV; Chang AL
    Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
    Metcalfe C; de Sauvage FJ
    Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
    Khalid B; Mukherjee S; Ibrahimi S; Cannon T; Gilles E; Moreau A; Razaq M
    Am J Ther; 2018; 25(3):e394-e396. PubMed ID: 29557803
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced treatment for basal cell carcinomas.
    Atwood SX; Whitson RJ; Oro AE
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma.
    Deng M; Marsch AF; Petronic-Rosic V
    Skinmed; 2017; 15(4):265-268. PubMed ID: 28859735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New perspectives in the management of basal cell carcinoma.
    Martín-Gorgojo A; Pastushenko I
    Actas Dermosifiliogr; 2014 Nov; 105(9):874-5. PubMed ID: 24934656
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
    Zhu GA; Li AS; Chang AL
    JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous Change in Basal-Cell Carcinoma with Drug Resistance.
    Ransohoff KJ; Tang JY; Sarin KY
    N Engl J Med; 2015 Sep; 373(11):1079-82. PubMed ID: 26352826
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
    Kunstfeld R
    Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.
    Kean S
    Science; 2009 Sep; 325(5945):1188. PubMed ID: 19729622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.